A Phase I, Double-Blind, Placebo-Controlled, Dose- Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 325568 Administered to Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- safety and tolerability
研究概览
简要总结
The primary purpose of this trial is to assess the safety of ISIS 325568 when given at increasing single doses and to assess the safety of the same doses when given multiple times.
详细描述
To evaluate the safety of a single subcutaneous injection of ISIS 325568 administered at four increasing dose levels (50, 100, 200, 400 mg/week) and to evaluate the safety and tolerability of multiple doses of ISIS 325568 (three intravenous doses during Study Week 1, followed by once weekly subcutaneous administration for 5 weeks) at each of the four dose levels
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18 to 65 years
- •Males or females. Females must be non-pregnant and non-lactating, and either surgically sterile (hysterectomy, oophorectomy, or tubal ligation) or post-menopausal. Males must be surgically sterile, abstinent or if engaged in sexual relations of child-bearing potential, subject or partner must be using an acceptable contraceptive method during the trial and for 9 weeks after the last dose of study drug.
- •Give written informed consent to participate in study and availability for all study requirements
- •Fasting plasma glucose ≤ the upper limit of the laboratory's reference range (ULN)
- •HbA1C ≤ ULN
- •BMI < 30 kg/m2
排除标准
- •Clinically significant abnormalities in medical history or physical examination
- •Abnormalities on laboratory examination (ALT > ULN, AST > ULN, bilirubin > ULN, creatinine > ULN, urine protein positive by urine dipstick, platelets < lower limit of normal and any other clinically significant laboratory findings)
- •History of clinically significant abnormalities in coagulation parameters
- •Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus
- •Active infection requiring antiviral or antimicrobial therapy
- •Subjects on chronic or acute prescription medication may be permitted after discussion with the Isis Medical Monitor.
- •Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for > 1 year)
- •Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance
- •History of alcohol or drug abuse
- •Undergoing or have undergone treatment with another investigational drug, biologic agent or device within 90 days prior to Screening.
- •Blood donation within three months of screening
研究组 & 干预措施
A
50 mg ISIS 325568 vs Placebo, s.c. injection
干预措施: ISIS 325568 (Drug)
B
100 mg ISIS 325568 vs Placebo , s.c. injection
干预措施: ISIS 325568 (Drug)
C
200 mg ISIS 325568 vs Placebo , s.c. injection
干预措施: ISIS 325568 (Drug)
D
400 mg ISIS 325568 vs Placebo, s.c. injection
干预措施: ISIS 325568 (Drug)
AA
50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
干预措施: ISIS 325568 (Drug)
BB
100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
干预措施: ISIS 325568 (Drug)
CC
200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
干预措施: ISIS 325568 (Drug)
DD
400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
干预措施: ISIS 325568 (Drug)
结局指标
主要结局
safety and tolerability
时间窗: 30 days for single dose, 16 weeks for multi-dose
次要结局
- Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups.(4 days for single dose, 16 weeks for multi-dose)